Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Original Article

M.J. Dickinson, C. Carlo-Stella, F. Morschhauser, E. Bachy, P. Corradini, G. Iacoboni, C. Khan, T. Wróbel, F. Offner, M. Trněný, S.-J. Wu, G. Cartron, M. Hertzberg, A. Sureda, D. Perez-Callejo, L. Lundberg, J. Relf, M. Dixon, E. Clark, K. Humphrey, and M. Hutchings

N Engl J Med 2022;387:2220-2231

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
12/14/2022
Course expires: 
12/15/2024
Take course

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Take course